Journal
BIOMATERIALS
Volume 34, Issue 1, Pages 92-99Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2012.09.069
Keywords
Mesenchymal stem cells; Cardiogenic differentiation; EGFR; Compound 56; MicroRNA-133a
Funding
- Korea Science and Engineering Foundation
- Korea Government (MEST) [2011-0019243, 2011-0019254]
- Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A120478]
- Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea [A085136]
Ask authors/readers for more resources
Human bone marrow-derived mesenchymal stem cells (hMSCs) are an attractive candidate for cell therapy in heart disease. Low survival and incomplete electromechanical integration between resident cardiomyocytes and transplanted hMSCs remain unsolved. In order for an infarcted heart to tolerate transplantation, differentiation capacity in stem cells must be reinforced. In this study, we found that compound 56, an epidermal growth factor receptor (EGFR) inhibitor, promotes cardiogenic differentiation of hMSCs and the transplantation of hMSCs treated with compound 56 resulted in enhancement of heart functions. Furthermore, hMSCs transfected with microRNA-133a (miR-133a), which targets EGFR, were observed to express cardiac-specific markers. We also discovered that luciferase activity is exclusively decreased by targeting EGFR in hMSCs transfected with miR-133a mimic. These results suggest that EGFR plays a key role in the regulation of cardiogenic differentiation in hMSCs. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available